The CSO of Enanta Pharmaceuticals (NASDAQ: ENTA) is Selling SharesBy Carrie Williams
Following Yat Sun Or’s last ENTA Sell transaction on January 19, 2016, the stock climbed by 5.6%.
The company has a one year high of $35.06 and a one year low of $20.39. ENTA’s market cap is $595.6M and the company has a P/E ratio of 27.94. Currently, Enanta Pharmaceuticals has an average volume of 185K.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It focuses on the following disease targets: Hepatitis C virus, Hepatitis B virus, Non-alcoholic Steatohepatitis, and Respiratory syncytial virus. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.